Hamilton, M.

patient erlotinib cancer study sample lurtotecan nx 211 toxicity skin toxicity concentration 150 mg blood activity light response grade escalation phase treatment plasma trial inhibitor level exposure camptothecin increase growth infusion month blood samples anticancer activity erlotinib doses dose escalation solution pharmacokinetic laboratory light mec concentrations cutsem compound factor disease range oncol intrapatient dose escalation product result topoisomerase volume british journal sodium light phase i 2.0 ambient temperature 50- l aliquots 30- min i.v nsclc receptor number laboratory dilution epidermal research analogue plasma samples anticancer analysis intrapatient chemical qc samples netherland incubation camptothecin analogues table topotecan tumour degradation non-small sodium cancer institute ammonium